Search is Powered by Google
Prostate / Prostate Cancer News

MIR-1256b Induces Androgen-Independent Growth Of Prostate Cancer Cells

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Cancer / Oncology
Article Date: 08 Jun 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

ORLANDO, FL (UroToday.com) - Increasing evidence has shown that some aberrantly-expressed microRNAs (miRNAs) are involved in human carcinogenesis. Recently, a group of researchers from UC Davis found that androgen-independent (AI) LNCaP sublines (cds cells) express markedly increased miR-125b compared to the parental LNCaP cells, suggesting that this miRNA may play a role in the pathogenesis of prostate cancer (CaP). Since the association of miR-125b with CaP is totally unknown, the purpose of this study was to understand the role of this miRNA in CaP.

They used LNCaP and cds1 cells cultured in androgen-depleted medium and transfected with synthetic miR-125b and antimiR-125b, respectively, and cell proliferation was assessed using the WST-1 assay. Chromatin immunoprecipitation (ChIP) assay was used to determine the loading of androgen receptor (AR) onto the 5'-DNA region of miR-125b. To test whether BAK1 mRNA is a direct target of miR-125b, a luciferase assay was performed in AR-negative DU145 cells to evaluate the effects of miR-125b on the 3'-untranslated region (3'-UTR) of the BAK1 gene.

The researchers report that synthetic miR-125b stimulated the growth of LNCaP cells in the absence of androgens. These cells retained typical morphological features. In contrast, in cds cells, inhibition of miR-125b activity using synthetic anti-miR-125b inhibited proliferation of these cells and this was accompanied by a reduction of cell size and increased neuroendocrine features. These data suggest that miR-125b stimulates the AI growth of LNCaP cells. Since the synthetic androgen R1881 upregulated the expression of miR-125b, we examined whether the AR is able to load to the 5'-DNA region of the miR-125b locus to serve as a transcriptional factor. Results from ChIP assays showed that treatment of LNCaP cells with R1881 induced a 4.5- to 6.5-fold increase in AR loading at the 5' region of miR-125b, suggesting that androgen-AR signaling regulates the expression of miR-125b in CaP cells. Since microarray assays demonstrated a > 2.0 fold downregulation of the BAK1 gene in miR-125b-treated LNCaP cells, and since the 3'-UTR of BAK1 gene contains a miR-125b binding site, luciferase assay of this 3'-UTR was performed. It was found that synthetic miR-125 induced a 50-60% reduction of the luciferase activity.

This data indicates that 1) miR-125b acts as an oncogene, contributing to the pathogenesis of CaP; 2) AR regulates the expression of miR-125b and 3) miR-125b targets the BAK1 gene.

Presented by Xu-Bao Shi, Lingru Xue, Joy Yang, Christopher P Evans, Ralph W deVere White at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Prostate Cancer Drug Breakthrough For Aggressive Form Of Disease
22 Jul 2008
A new trial drug called abiraterone has shown a high success rate at treating men with an aggressive, drug resistant, and often fatal form of prostate cancer. 70 to 80 per cent of the men on the trial experienced dramatic...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Improving Health Care image Improving Health Care

Improvements are necessary to make sure Americans get the best quality health care and that money for this care is being spent as effectively as possible. Listen as experts -- both in government and in the private sector -- describe some of the steps taken to improve the health care system...

View more videos...